Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …

Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …

Background Adding radiotherapy (RT) to systemic therapy improves progression-free
survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Background For patients with non-small-cell lung cancer (NSCLC) and multiple brain
metastases, whole-brain irradiation (WBI) is a standard-of-care treatment, but its effects on …

Purpose Whereas whole-brain radiotherapy (WBRT) has been the standard treatment of
brain metastases (BMs), stereotactic radiosurgery (SRS) is increasingly preferred to avoid …

Introduction The aim of the current study was to investigate whether consolidative local
ablative therapy (LAT) can improve the survival of patients with stage IV EGFR-mutant …